Celgene announced interim results from a Phase I/II study for its investigational therapy iberdomide, or CC-220, combined with dexamethasone, in patients with relapsed/refractory multiple myeloma, which was found to be safe and was able to control the disease in almost 90% of trial participants. The preliminary data were unveiled during a presentation at the 2019 annual meeting of the American Society of Clinical Oncology.
Celgene reports on interim data for myeloma candidate iberdomide
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.